BioCardia
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Contact Us

Press Releases

BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering

June 16, 2015

SAN CARLOS, CA –BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering (IPO) of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. In connection with the proposed IPO, BioCardia has applied to list its common stock on the NASDAQ Global Market under the symbol “BCDA.”

Cantor Fitzgerald & Co. is acting as the sole bookrunner for the proposed offering. Roth Capital Partners and Maxim Group LLC are acting as co-managers for the proposed offering.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from the offices of Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor, New York, New York 10022 or by telephone at 212-829-7122 or by email at Prospectus@Cantor.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About BioCardia, Inc.
BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs.  Its lead therapeutic candidate is the CardiAMP Cell Therapy System, which is a comprehensive treatment that includes a companion diagnostic, and is comprised of (i) a cell potency screening test, (ii) a point of care cell processing platform, and (iii) a biotherapeutic delivery system.  BioCardia is committed to applying its expertise in the fields of autologous and allogenic cell-based therapies to improve the lives of patients with cardiovascular conditions. The company is based in San Carlos, California.

Contact:
Gary Titus
Chief Financial Officer
BioCardia, Inc.
(650) 226-0126
gtitus@biocardia.com